BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $11 million versus the consensus estimate of $6.77 million.

Financial Outlook for 2015

Based upon current trends, assumptions, and development plans, BioCryst expects its 2015 net operating cash use to be in the range of $8 to $18 million, upon adjusting the Company's previously predicted range for the first nine months of operations and including the favorable impact of the Seqirus transaction. In addition, BioCryst continues to expect its operating expenses to be within the range of $75 to $95 million. Our operating expense range excludes equity-based compensation expense due to the difficulty in accurately projecting this expense, as it is significantly impacted by the volatility and price of the Company's stock, as well as vesting of the Company's outstanding performance-based stock options.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.